Related Experiment Video
Updated: Jan 4, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.5K
ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
Buru Chang1, Yonghwa Choi1, Minji Jeon1
1Department of Computer Science and Engineering, Korea University, Seoul 02841, Korea.
Genes
|November 10, 2019
Summary
Predicting antidepressant response is crucial for major depressive disorder treatment. The proposed Antidepressant Response Prediction Network (ARPNet) model accurately forecasts patient response to antidepressants, outperforming existing machine learning methods.
Area of Science:
- Psychiatry and Computational Neuroscience
Background:
- Treating major depressive disorder (MDD) is challenging due to the delayed onset of antidepressant effects, leading to increased risks and costs.
- Current prediction models often struggle to integrate diverse patient data like neuroimaging and genetic variants effectively.
- Existing machine learning models may not identify the most suitable antidepressant for individual patients.
Purpose of the Study:
- To develop an accurate antidepressant response prediction model to overcome the limitations of current treatments.
- To propose a novel neural network-based model, Antidepressant Response Prediction Network (ARPNet), for predicting patient response to antidepressants.
- To enhance clinical decision-making by providing a tool for personalized antidepressant selection.
Main Methods:
- Literature survey and data-driven feature selection to identify key patient predictors.
- Development of the Antidepressant Response Prediction Network (ARPNet) utilizing patient and antidepressant prescription representation layers.
- Capturing high-dimensional patterns from patient features and antidepressant characteristics to predict response degree.
Main Results:
- The proposed ARPNet model demonstrated superior performance in predicting antidepressant response compared to traditional machine learning models.
- Experimental evaluations confirmed the effectiveness of ARPNet in forecasting treatment outcomes.
- The study highlighted the applicability of ARPNet in practical clinical scenarios and downstream applications.
Conclusions:
- ARPNet offers a significant advancement in predicting antidepressant response for major depressive disorder.
- The model's ability to integrate diverse patient data and predict response degree facilitates personalized medicine.
- ARPNet shows promise for improving treatment efficacy and reducing healthcare costs associated with MDD management.
Keywords:
antidepressant response predictionmajor depressive disorderneural networkpatient representationMore Related Videos
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
741
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
741
01:25Antidepressant Drugs: Overview
1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
01:21G-protein Coupled Receptors
131.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.3K
01:27Depressive Disorders: MDD and Dysthymia
529
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
529
01:18Depression: Overview
723
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
723
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K